The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Orphan drug designation granted to BI-1206 antibody for the treatment of follicular lymphoma
On January 19, 2022, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to BI-1206, an anti-FcyRllB antibody, for the treatment of follicular lymphoma (FL).1
FL is an indolent B-cell lymphoma that represents 20‒30% of all non-Hodgkin lymphomas (NHL). The agent is currently being investigated in a phase I/II trial in combination with rituximab for the treatment of NHL, which includes patients with FL, mantle cell lymphoma, and marginal zone lymphoma who have relapsed or are refractory to rituximab. Results suggest BI-1206 may help to restore the response to rituximab in patients with few treatment alternatives, especially so for patients with FL.
The monoclonal antibody BI-1206 has also previously received orphan drug designation from the FDA for the treatment of mantle cell lymphoma, an aggressive form of NHL, in January 2019.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content